Remodeling Failing Human Myocardium With Hybrid Cell/Matrix and Transmyocardial Revascularization

Given the limited treatment options for advanced heart failure, the intrinsic regenerative properties of stem cells have been evaluated for myocardial remodeling. Previous stem cells techniques for myocardiocyte remodeling have been limited by the low cellular retention. Presented is a hybrid approach for remodeling infarcted myocardium through implantation of allogeneic human amniotic fluid–derived mesenchymal stem cells within micronized human allograft-derived liquid matrix during the performance of transmyocardial revascularization (TMR). Given the induced increase in vascular density from TMR, we hypothesize that it may serve as a therapeutic delivery system for stem cell placement into damaged myocardium. We present a patient with ischemic cardiomyopathy and refractory angina, who clinically improved after this hybrid therapy of intraoperative TMR and placement of amniotic fluid–derived mesenchymal stem cells and liquid matrix within the TMR channels. Noninvasive testing of myocardial viability biomarkers utilizing both cardiac magnetic resonance imaging and thallium imaging supported the clinical improvement in cardiac symptom may be related to ventricular remodeling in a region of infarct with subsequent functional improvement.

[1]  Raymond B. Runyan,et al.  Clinical outcomes meta-analysis: measuring subendocardial perfusion and efficacy of transmyocardial laser revascularization with nuclear imaging , 2017, Journal of Cardiothoracic Surgery.

[2]  Raymond B. Runyan,et al.  Remodeling an infarcted heart: novel hybrid treatment with transmyocardial revascularization and stem cell therapy , 2016, SpringerPlus.

[3]  J. Moraleda,et al.  Amniotic membrane-derived stem cells: immunomodulatory properties and potential clinical application , 2014, Stem cells and cloning : advances and applications.

[4]  G. Scheiner-Bobis,et al.  Effect of extracorporeal shock wave on proliferation and differentiation of equine adipose tissue-derived mesenchymal stem cells in vitro. , 2013, American journal of stem cells.

[5]  Daniel Berman,et al.  Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial , 2012, The Lancet.

[6]  R. Shemin,et al.  The Society of Thoracic Surgeons practice guideline series: transmyocardial laser revascularization. , 2004, The Annals of thoracic surgery.

[7]  M. Coughlin Comparison of Transmyocardial Revascularization with Medical Therapy in Patients with Refractory Angina , 2001 .

[8]  M. Matsuzaki,et al.  Enhancement of angiogenesis by the implantation of self bone marrow cells in a rat ischemic heart model. , 2000, The Journal of surgical research.

[9]  Robert D. Dowling,et al.  Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. , 1999, The New England journal of medicine.

[10]  K. Horvath Transmyocardial Laser Revascularization , 1995, Journal of cardiac surgery.